FDA
-
-
-
-
-
-
-
Arvinas to Report First Quarter 2026 Financial Results on May 12, 2026
-
-
-
-
-
-
-
Arvinas to present vepdegestrant data at breast cancer symposium
-
-
-
-
-
-
-
Arvinas and Pfizer to out-license vepdegestrant commercialization rights
-
-
-
-
-
-
-
Arvinas Inc. (ARVN) Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer
-
-
-
-
-
-
-
Arvinas Inc. (ARVN) PT Lowered to $21 at Truist Securities
-
-
-
-
-
-
-
Arvinas (ARVN) and Pfizer (PFE) Announce Initial Phase 1b Data from the TACTIVE-U Sub-Study of Vepdegestrant in Combination with Abemaciclib at 2024 San Antonio Breast Cancer Symposium
-
-
-
-
-
-
-
Milestone Pharmaceuticals Refreshes Board of Directors
-
323,573 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

